SERVIER MONDE
Servier is a global independent pharmaceutical group founded in 1954, focused on oncology, cardiovascular, cardiometabolic, and neurological disorder treatments across more than 130 countries.
SERVIER MONDE is a global independent pharmaceutical group founded in 1954. The company operates in more than 130 countries, employs over 21,900 people, and serves approximately 100 million patients daily. Its governance structure is rooted in a non-profit foundation, distinguishing it from many of its publicly traded peers in the pharmaceutical industry.
The group's research and development efforts concentrate on several therapeutic areas: oncology, cardiovascular medicine, cardiometabolism, and rare neurological disorders. Oncology commands roughly 70% of the R&D budget, with the company investing close to 20% of its brand-name medicine revenue into research across 6 research centers and 19 International Centers for Therapeutic Research. Products such as TIBSOVO and VORANIGO represent its work in cancer treatment.
Servier's stated values emphasise innovation, patient-centred care, and collaborative growth. The company positions itself as driven by therapeutic progress, with a governance model designed to maintain long-term independence in its strategic direction.